Design of the genO‑MC38-hPD-L1-hCD47-LZ cell line

The MC38 cell line was derived from C57BL/6 murine colon adenocarcinoma cells. They form solid tumors upon subcutaneous injection in immunocompetent mice.

We generated a genO-MC38-hPD-L1-hCD47-LZ clonal cell line expressing high levels of human PD-L1 (CD274 NCBI GeneID: 29126) and human CD47 (NCBI GeneID: 961), and an optimized dual fusion reporter luciferase-ZsGreen (LZ). These cells are invalidated for murine Pd-l1 (Cd274, NCBI Gene ID: 60533). genO-MC38-hPD-L1-hCD47-LZ cells form solid tumors in vivo, most efficiently in genO-hCD47/hSIRPα mice. Isogenic wild-type (WT) and luciferase-ZsGreen (LZ) control clones are available.

Features

  • Form solid tumors upon subcutaneous injection in fully immunocompetent mice
  • PD-L1 and CD47 are entirely humanized
  • Express a luciferase-ZsGreen (LZ) fusion reporter
  • Injected cells can be followed in vivo and ex vivo with our LZ reporter

Clients

No items found.

Supply & delivery

  • Breeding facilities in US and Europe
  • Delivery door-to-door worldwide
  • Certified health status from professional breeders

Validation data

Discover related products to

genO-MC38-hPD‑L1-hCD47-LZ

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
CD47
SIRPα
ICP (single-target)
ICP (multi-target)
Immune checkpoint

genO-hCD47/hSIRPα

Double-humanized genO‑hCD47/hSIRPα immunocompetent mice enable the efficacy assessment of anti-CD47/SIRPα.

Immune checkpoint
CTLA-4
PD-1
ICP (multi-target)

genO-hPD‑1/hCTLA‑4

The genO‑hPD-1/hCTLA-4 mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint PD-1 and/or CTLA-4 in fully immunocompetent mice.

Immune checkpoint
PD-1
GITR
ICP (multi-target)
GITRL

genO-hPD‑1/hGITR/hGITRL

The genO-hPD-1/hGITR/hGITRL mouse model enables in vivo efficacy assessment and profiling of antibodies targeting human immune checkpoint PD-1, GITR and/or GITRL in fully immunocompetent mice.

Immune checkpoint
PD-1
PD-L1
ICP (multi-target)

genO-hPD‑1/hPD‑L1

The genO‑hPD-1/hPD-L1 mouse model enables in vivo efficacy assessment and profiling of molecules targeting the human PD-1/PD-L1 axis in fully immunocompetent mice.

Immune checkpoint
PD-1
TIM3
ICP (multi-target)

genO-hPD‑1/hTIM3

The genO‑hPD‑1/hTIM3 mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint PD-1 and/or TIM3 in fully immunocompetent mice.

Immune checkpoint
PD-1
VISTA
ICP (multi-target)

genO-hPD‑1/hVISTA

The genO‑hPD‑1/hVISTA mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint PD-1 and/or VISTA in fully immunocompetent mice.

PD-1
Immune checkpoint
ICP (single-target)

genO‑hPD‑1

The genO‑hPD‑1 mouse enables the in vivo efficacy assessment and profiling of compounds targeting the human immune checkpoint PD-1 in fully immunocompetent mice

Immune checkpoint
PD-1
Lag3
ICP (multi-target)

genO‑hPD‑1/hLAG3

The genO‑hPD‑1/hLAG3 mouse model enables in vivo efficacy assessment and profiling of antibodies targeting human immune checkpoint PD-1 and/or LAG3 in fully immunocompetent mice.

Immune checkpoint
PD-L1
CT26

genO-CT26-Pd-l1KO

The Pd-l1 Knockout colon carcinoma CT26 cell line is invalidated for murine Pd-l1 and can be used for target validation and mechanistic studies.

CT26
Immune checkpoint
CD39

genO-CT26-hCD39-LZ

The genO-CT26-hCD39-LZ clonal cell line expresses high levels of human/mouse chimeric CD39, and forms solid tumors in vivo.

CT26
Immune checkpoint
EpCAM

genO-CT26-hEpCAM-LZ

genO-CT26-hEpCAM-LZ clonal cell line expresses high levels of human EpCAM, and forms solid tumors in vivo.

CD19
EL4
Immune checkpoint

genO-EL4-hCD19-LZ

genO-EL4-hCD19-LZ cells form tumors in syngeneic models, upon subcutaneous and systemic (i.v.) injection, in immunocompetent mice.

CD20
Immune checkpoint
EL4

genO-EL4-hCD20-LZ

The genO-EL4-hCD20-LZ clonal cell line expresses high levels of human CD20.

PD-L1
Immune checkpoint

genO-MC38-Pd-l1KO

The Pd-l1 Knockout colon adenocarcinoma MC38 cell line is invalidated for murine Pd-l1 and can be used for target validation and mechanistic studies.

CD39
MC38
Immune checkpoint

genO-MC38-hCD39-LZ

The genO-MC38-hCD39-LZ cells homogeneously express human CD39 in vitro, and form infiltrated tumors in immunocompetent mice.

PD-L1
Immune checkpoint
MC38
PD-1

genO-MC38-hPD-L1-LZ

The genO-MC38-hPD-L1-LZ clonal cell line expresses high levels of  human PD-L1 and forms solid tumors in vivo. An optimized version of a  luciferase-ZsGreen (LZ) fusion protein is also stably expressed for in vivo imaging and ex vivo tracking.

MC38
Immune checkpoint
PD-L1

genO-MC38-hPD-L1-hFAP-LZ

The genO-MC38-hPD-L1-hFAP-LZ clonal cell line expresses human PD-L1, human FAP and an optimized dual fusion reporter, luciferase-ZsGreen (LZ)

MC38
Immune checkpoint
PD-L1
HER2

genO-MC38-hPD-L1-hHER2-LZ

The genO-MC38-hPD-L1-hHER2-LZ clonal cell line expresses high levels of human PD-L1  and human HER2.

PD-L1
Immune checkpoint
CT26

genO-hCT26-hPD‑L1

The humanized hPD-L1 syngeneic clonal colon carcinoma CT26 cell line expresses high levels of human PD-L1 and forms solid tumors in vivo.

Humanized genO‑MC38-hPD-L1-hCD47-LZ reporter tumor cell line

Get in touch about

Let us know how we can help

Scientific excellence

From model design to experimental results
Featured in 600+ scientific articles

Collaborative approach

Collaboration with 17 Top Pharmas,
170+ Biotechs and 380+ Academic Institutions

Robust validation data on catalog models

Generated with biopharma partners and in-house

Innovative technologies

and guaranteed freedom to operate

Easy access to models

Models with certified health status from professional breeders in US and Europe